InspireMD Amends Warrants to Unlock Up to $11M Ahead of FDA Decision
NSPR sits 22% above its 52-week low of $0.63 on light trading volume (0.3× avg).
Summary
InspireMD amended existing Series J and K warrants to align exercise with the anticipated Q4 2026 FDA approval of CGuard Prime 80 cm. The amendments set a new exercise price of $0.7674 for 50% of Series J and all Series K warrants, potentially raising up to $11 million. No new warrants were issued, so dilution is limited to existing holders. This follows a delisting notice and going concern warnings, making the capital infusion critical for the TCAR launch. The company expects FDA approval in Q4 2026, which would trigger the warrant exercise window.
At the time of this announcement, NSPR was trading at $0.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.7M. The 52-week trading range was $0.63 to $2.57. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.